Ethical dilemmas and malfunctions in clinical trials research

Annals of Internal Medicine

Volumn 156, Issue 10, 2012, Pages 746-747

  Pocock, Stuart J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DRONEDARONE; TORCETRAPIB;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DECISION MAKING; DRUG WITHDRAWAL; EDITORIAL; ETHICS; HEAD INJURY; HEART ATRIUM FIBRILLATION; HUMAN; MORTALITY; PRIORITY JOURNAL;

EID: 84861163751     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-10-201205150-00015     Document Type: Editorial

References (16)

1. Fan VS, Gaziano JM, Lew R, Bourbeau J, Adams SG, Leatherman S, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations. A randomized, controlled trial. Ann Intern Med. 2012;156:673-83.
2. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:218-28.
3. Pocock SJ. Current controversies in data monitoring for clinical trials. Clin Trials. 2006;3:513-21.
4. DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet. 1999;354:1983-8.
5. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.
6. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765-72.
7. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-22.
8. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al; PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268-76.
9. Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, et al; CRASH trial collaborators. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet. 2004;364:1321-8.
10. Pocock SJ. When to stop a clinical trial. BMJ. 1992;305:235-40.
11. Petersen LA, Simpson K, SoRelle R, Urech T, Chitwood SS. How variability in the institutional review board review process affects minimal-risk multisite health services research. Ann Intern Med. 2012;156:728-35.
12. Martyn C. The ethical bureaucracy [Editorial]. QJM. 2003;96:323-4.
13. Gaw A. Exposing unethical human research: the transatlantic correspondence of Beecher and Pappworth. Ann Intern Med. 2012;156:150-5.
14. Al-Shahi R. Research ethics committees in the UK-the pressure is now on research and development departments. J R Soc Med. 2005;98:444-7.
15. Califf RM. Clinical trials bureaucracy: unintended consequences of wellintentioned policy. Clin Trials. 2006;3:496-502.
16. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, Harrington RA, Califf RM, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360:816-23.